Avicenna J Med Biotech arij002 Avicenna Journal of Medical Biotechnology 2008-2835 2008-4625 Avicenna Research Institute ajmb224 Construction of CTLA-4-Ig Fusion Gene in pBudCE4.1 Expression Vector Yazdanpanah-SamaniMahsaDepartment of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, IranMahmoudi MaymandElhamSchool of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, IranNational Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, IranJahangeerfamTayebehDepartment of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, IranGhaderiAbbasDepartment of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran 7 4 179 181 5 5 2015 12 7 2015

<p>Background: CTLA-4 inhibitory signals prevent cell cycle progression and IL-2 production, leading to a halt on an ongoing immune response. CTLA4-Ig fusion proteins contain the extracellular domain of CTLA-4 and Fc fragment of human IgG antibody. In this study we aimed to fuse the <em>ctla-4</em> gene encoding the extracellular domain of CTLA-4 molecule with <em>igg1</em> gene encoding Fc region of human IgG.<br /> Methods: After primer design, PCR reaction was performed using pfu polymerase enzyme and specific primers. PCR amplified fragment was ligated into the vector containing the human <em>igg1</em> gene. The resulting fusion fragment of <em>ctla-4</em> and human <em>igg1</em> genes was ligated to pBudCE4.1 expression vector.<br /> Results: Extracellular domain of <em>ctla-4</em> gene was ligated to <em>igg1</em> gene and then <em>ctla4-ig</em> fragment was cloned into pBudCE4.1 vector. Construction of the expression vector was confirmed by restriction pattern analysis and sequencing.<br /> Conclusion: By confirming the construct, in the next step, the recombinant DNA will be used to produce CTLA4-Ig recombinant protein for the clinical uses.</p>